{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-298474","form_type":"8-K","ticker":"ELVN","cik":"0001672619","company_name":"Enliven Therapeutics, Inc.","filed_at":"2022-12-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.655185+00:00","generated_at":"2026-06-21T09:39:32.056722+00:00","sec_items":["8.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Imara Inc. announces expiration of HSR Act waiting period for merger with Enliven Therapeutics","bullets":["HSR Act waiting period for merger with Enliven Therapeutics expired on Nov 28, 2022, without extension or request for additional information.","This expiration satisfies one of the conditions to closing the merger previously announced on Oct 13, 2022.","Upon closing, Merger Sub will merge with Enliven, making Enliven a wholly-owned subsidiary of Imara."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-298474","json":"https://secwatch.observer/filing/0001193125-22-298474.json","markdown":"https://secwatch.observer/filing/0001193125-22-298474.md","text":"https://secwatch.observer/filing/0001193125-22-298474.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1672619/000119312522298474/0001193125-22-298474-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1672619/000119312522298474/d415058d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T09:39:32.056722+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}